We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer. Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2024...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.02 | 0.0394244037059 | 50.73 | 50.75 | 45.95 | 602685 | 48.13816046 | CS |
4 | -2.84 | -5.29949617466 | 53.59 | 58.06 | 45.95 | 643057 | 52.71977938 | CS |
12 | 5.83 | 12.9786286732 | 44.92 | 58.06 | 41.23 | 635329 | 49.4980016 | CS |
26 | 5.06 | 11.074633399 | 45.69 | 58.06 | 34.5125 | 644452 | 46.19142008 | CS |
52 | 41.88 | 472.153325817 | 8.87 | 65.6 | 7.79 | 643710 | 45.24827788 | CS |
156 | 32.87 | 183.836689038 | 17.88 | 65.6 | 5.65 | 280200 | 37.9234942 | CS |
260 | 16.75 | 49.2647058824 | 34 | 65.6 | 5.65 | 269961 | 36.79164867 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions